Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Orbach

Showing results (1-10 of 351) with videos related to

Pageof 36
Sort By:
Bulletin Du Cancer|November 9, 2016
[Teenagers and young adults with cancer: A population with specificities better and better recognized]Daniel Orbach
Bulletin Du Cancer|October 9, 2014
[Discovery of a new mutation in MYOD1 characterizes a subset of aggressive embryonal rhabdomyosarcoma partnering with mutations of the PI3K-AKT pathway]Daniel Orbach
Bulletin Du Cancer|May 3, 2015
[Organization and long-term follow-up of adults treated for cancer during childhood: A necessity in 2015]Daniel Orbach, Claire Berger
Bulletin Du Cancer|March 18, 2020
[Desmoid type fibromatosis, from radical excision to molecular extirpation]Nicolas Penel, Daniel Orbach
Bulletin Du Cancer|October 3, 2022
[Importance of harmonized supportive care guidelines and practice analyses in pediatric oncology]Virginie Gandemer, Daniel Orbach
Bulletin Du Cancer|January 30, 2023
[Drug approval: Crizotinib in unresectable or refractory ALK-positive pediatric inflammatory myofibroblastic tumors]Anne Tenaillon, Daniel Orbach
Bulletin Du Cancer|September 22, 2015
[DICER1: A new model of epigenetic tumor suppressor gene]Jean-Sébastien Diana, Daniel Orbach
Bulletin Du Cancer|December 21, 2020
[Interactions optimization between pediatricians and adults' physicians for patient benefit in oncology]Virginie Gandemer, Daniel Orbach, Isabelle Pellier
Pediatric Blood & Cancer|March 15, 2019
Reply to "Pathological prognostication of pediatric adrenocortical tumors: Is a gold standard emerging?"Cécile Picard, Daniel Orbach, Frédérique Dijoud
Bulletin Du Cancer|April 17, 2026
Toxicity of NTRK inhibitors: A clinical overviewRobin Coppin, Lauriane Lemelle, Daniel Orbach
Pageof 36

Showing results (1-10 of 351) with videos related to

Sort By:
Pageof 36
Bulletin Du Cancer|November 9, 2016
[Teenagers and young adults with cancer: A population with specificities better and better recognized]Daniel Orbach
Bulletin Du Cancer|October 9, 2014
[Discovery of a new mutation in MYOD1 characterizes a subset of aggressive embryonal rhabdomyosarcoma partnering with mutations of the PI3K-AKT pathway]Daniel Orbach
Bulletin Du Cancer|May 3, 2015
[Organization and long-term follow-up of adults treated for cancer during childhood: A necessity in 2015]Daniel Orbach, Claire Berger
Bulletin Du Cancer|March 18, 2020
[Desmoid type fibromatosis, from radical excision to molecular extirpation]Nicolas Penel, Daniel Orbach
Bulletin Du Cancer|October 3, 2022
[Importance of harmonized supportive care guidelines and practice analyses in pediatric oncology]Virginie Gandemer, Daniel Orbach
Bulletin Du Cancer|January 30, 2023
[Drug approval: Crizotinib in unresectable or refractory ALK-positive pediatric inflammatory myofibroblastic tumors]Anne Tenaillon, Daniel Orbach
Bulletin Du Cancer|September 22, 2015
[DICER1: A new model of epigenetic tumor suppressor gene]Jean-Sébastien Diana, Daniel Orbach
Bulletin Du Cancer|December 21, 2020
[Interactions optimization between pediatricians and adults' physicians for patient benefit in oncology]Virginie Gandemer, Daniel Orbach, Isabelle Pellier
Pediatric Blood & Cancer|March 15, 2019
Reply to "Pathological prognostication of pediatric adrenocortical tumors: Is a gold standard emerging?"Cécile Picard, Daniel Orbach, Frédérique Dijoud
Bulletin Du Cancer|April 17, 2026
Toxicity of NTRK inhibitors: A clinical overviewRobin Coppin, Lauriane Lemelle, Daniel Orbach
Pageof 36